The U.S. Food and Drug Administration (FDA) on Thursday announced an expedited plan to implement artificial intelligence (AI) across all FDA centers by June 30 in a bid to speed up the review process of new drugs.
The decision comes
FDA to speed up AI rollout to accelerate drug reviews
